Immunodominance Among EBV-Derived Epitopes Restricted by HLA-B27 Does Not Correlate with Epitope Abundance in EBV-Transformed B-Lymphoblastoid Cell Lines1

Using synthetic peptides, the HLA-B27-restricted CTL response to EBV in asymptomatic virus carriers has been mapped to four epitope regions in EBV latent cycle Ags. One of these peptide-defined epitopes (RRIYDLIEL) tends to be immunodominant and is recognized in the context of all three B27 subtypes studied, B*2702, B*2704, and B*2705. The other peptide-defined epitopes induce responses only in the context of one subtype, the immunogenic combinations being RRARSLSAERY/B*2702, RRRWRRLTV/B*2704, and FRKAQIQGL/B*2705. We used immunoaffinity chromatography to isolate the naturally presented viral peptides associated with these MHC class I molecules on the surface of EBV-transformed B-LCL. Using CTL reconstitution assays in conjunction with mass spectrometry, we established that the naturally processed and presented peptides are identical with the previously identified synthetic sequences. Despite the subtype-specific immunogenicity of three of the four epitopes, all four epitope peptides were found in association with each of the three different HLA-B27 subtypes. Indeed, those peptides that failed to induce a response in the context of a particular HLA-B27 subtype were frequently presented at greater abundance by that subtype than were the immunogenic peptides. Furthermore, among the peptides that did induce a response, immunodominance did not correlate with epitope abundance; in fact the immunodominant RRIYDLIEL epitope was least abundant, being present at less than one copy per cell. The relationship of this unexpected finding to the persistence of EBV is discussed.

[1]  S. Carr,et al.  Mass Spectrometry in Biology & Medicine , 2000, Humana Press.

[2]  C. Herberts,et al.  A single naturally processed measles virus peptide fully dominates the HLA‐A*0201‐associated peptide display and is mutated at its anchor position in persistent viral strains , 2000, European journal of immunology.

[3]  V. Engelhard,et al.  The Density of Peptides Displayed by Dendritic Cells Affects Immune Responses to Human Tyrosinase and gp100 in HLA-A2 Transgenic Mice1 , 2000, The Journal of Immunology.

[4]  A. Rickinson,et al.  Cytotoxic T-Lymphocyte Responses to a Polymorphic Epstein-Barr Virus Epitope Identify Healthy Carriers with Coresident Viral Strains , 2000, Journal of Virology.

[5]  J. Shabanowitz,et al.  Sequencing the Primordial Soup , 2000 .

[6]  A. Gambotto,et al.  Identification of naturally processed and HLA-presented Epstein-Barr virus peptides recognized by CD4(+) or CD8(+) T lymphocytes from human blood. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[7]  J. Yewdell,et al.  Modification of Cysteine Residues In Vitro and In Vivo Affects the Immunogenicity and Antigenicity of Major Histocompatibility Complex Class I–restricted Viral Determinants , 1999, The Journal of experimental medicine.

[8]  S. Rowland-Jones,et al.  A re-evaluation of the frequency of CD8+ T cells specific for EBV in healthy virus carriers. , 1999, Journal of immunology.

[9]  A. Rickinson,et al.  HLA-B27 subtype polymorphism and CTL epitope choice: studies with EBV peptides link immunogenicity with stability of the B27:peptide complex. , 1998, Journal of immunology.

[10]  R. Zinkernagel,et al.  Comparison of activation versus induction of unresponsiveness of virus-specific CD4+ and CD8+ T cells upon acute versus persistent viral infection. , 1998, Immunity.

[11]  H. Rammensee,et al.  Protective Immunity Does Not Correlate with the Hierarchy of  Virus-specific Cytotoxic T Cell Responses to Naturally Processed Peptides , 1998, The Journal of experimental medicine.

[12]  A. Rickinson,et al.  Relationship between peptide binding and T cell epitope selection: a study with subtypes of HLA-B27. , 1998, International immunology.

[13]  P. Cresswell,et al.  Mechanisms of MHC class I--restricted antigen processing. , 1998, Annual review of immunology.

[14]  P. Paz,et al.  Minors held by majors: the H13 minor histocompatibility locus defined as a peptide/MHC class I complex. , 1997, Immunity.

[15]  D. Busch,et al.  MHC class I antigen processing of Listeria monocytogenes proteins: implications for dominant and subdominant CTL responses , 1997, Immunological reviews.

[16]  E. Pamer,et al.  Immunodominant and subdominant CTL responses to Listeria monocytogenes infection. , 1997, Journal of immunology.

[17]  D. Moss,et al.  Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection. , 1997, Annual review of immunology.

[18]  J. Yewdell,et al.  MHC class I-associated peptides produced from endogenous gene products with vastly different efficiencies. , 1997, Journal of immunology.

[19]  A. Agulnik,et al.  The HLA-A*0201-restricted H-Y antigen contains a posttranslationally modified cysteine that significantly affects T cell recognition. , 1997, Immunity.

[20]  Alan G. Marshall,et al.  Stored waveform inverse Fourier transform (SWIFT) ion excitation in trapped-ion mass spectometry: Theory and applications , 1996 .

[21]  N. Shastri,et al.  Alloreactive CD8+ T cells can recognize unusual, rare, and unique processed peptide/MHC complexes. , 1996, Journal of immunology.

[22]  J. Albar,et al.  Binding of peptides naturally presented by HLA-B27 to the differentially disease-associated B*2704 and B*2706 subtypes, and to mutants mimicking their polymorphism. , 1996, Tissue antigens.

[23]  C. Rice,et al.  Differential cytotoxic T-lymphocyte responsiveness to the hepatitis B and C viruses in chronically infected patients , 1996, Journal of virology.

[24]  G. Cooper,et al.  Frequency of multiple Epstein-Barr virus infections in T-cell-immunocompromised individuals , 1996, Journal of virology.

[25]  H. Eisen,et al.  Evidence that a single peptide-MHC complex on a target cell can elicit a cytolytic T cell response. , 1996, Immunity.

[26]  J. Berzofsky,et al.  Selective expansion of high- or low-avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[27]  A. Abbas,et al.  The roles of costimulation and Fas in T cell apoptosis and peripheral tolerance. , 1996, Immunity.

[28]  V. Levitsky,et al.  The life span of major histocompatibility complex-peptide complexes influences the efficiency of presentation and immunogenicity of two class I-restricted cytotoxic T lymphocyte epitopes in the Epstein-Barr virus nuclear antigen 4 , 1996, The Journal of experimental medicine.

[29]  J. Shabanowitz,et al.  An HLA-A2-restricted tyrosinase antigen on melanoma cells results from posttranslational modification and suggests a novel pathway for processing of membrane proteins , 1996, The Journal of experimental medicine.

[30]  R. J. Cohen,et al.  The law of mass action governs antigen-stimulated cytolytic activity of CD8+ cytotoxic T lymphocytes. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[31]  R. Anderson,et al.  Antigen processing in vivo and the elicitation of primary CTL responses. , 1995, Journal of immunology.

[32]  B. Moss,et al.  The cytotoxic T lymphocyte response to multiple hepatitis B virus polymerase epitopes during and after acute viral hepatitis , 1995, The Journal of experimental medicine.

[33]  H. Eisen,et al.  Variations in the number of peptide-MHC class I complexes required to activate cytotoxic T cell responses. , 1995, Journal of immunology.

[34]  R C Brower,et al.  Minimal requirements for peptide mediated activation of CD8+ CTL. , 1994, Molecular immunology.

[35]  L. Young,et al.  Epstein-Barr virus latency in blood mononuclear cells: analysis of viral gene transcription during primary infection and in the carrier state , 1994, Journal of virology.

[36]  R. Young,et al.  Naturally processed viral peptides recognized by cytotoxic T lymphocytes on cells chronically infected by human immunodeficiency virus type 1 , 1994, The Journal of experimental medicine.

[37]  R. Zinkernagel,et al.  T-cell-mediated immunopathology versus direct cytolysis by virus: implications for HIV and AIDS. , 1994, Immunology today.

[38]  P. Cresswell,et al.  Association of human class I MHC alleles with the adenovirus E3/19K protein. , 1994, Journal of immunology.

[39]  A Sette,et al.  Naturally processed peptides longer than nine amino acid residues bind to the class I MHC molecule HLA-A2.1 with high affinity and in different conformations. , 1994, Journal of immunology.

[40]  R. Zinkernagel,et al.  Peripheral clonal deletion of antiviral memory CD8+ T cells , 1993, European journal of immunology.

[41]  A. Rickinson,et al.  Different HLA-B27 subtypes present the same immunodominant Epstein-Barr virus peptide , 1993, The Journal of experimental medicine.

[42]  X. Jin,et al.  Quantitative analysis of the human immunodeficiency virus type 1 (HIV- 1)-specific cytotoxic T lymphocyte (CTL) response at different stages of HIV-1 infection: differential CTL responses to HIV-1 and Epstein- Barr virus in late disease , 1993, The Journal of experimental medicine.

[43]  Rolf M. Zinkernagel,et al.  Virus persistence in acutely infected immunocompetent mice by exhaustion of antiviral cytotoxic effector T cells , 1993, Nature.

[44]  R. Henderson,et al.  Characterization of peptides bound to the class I MHC molecule HLA-A2.1 by mass spectrometry. , 1992, Science.

[45]  D. R. Madden,et al.  Identification of self peptides bound to purified HLA-B27 , 1991, Nature.

[46]  U. Nater,et al.  Epstein-Barr virus. , 1991, The Journal of family practice.

[47]  S. Burrows,et al.  Cytotoxic T-cell clones discriminate between A- and B-type Epstein-Barr virus transformants , 1988, Nature.

[48]  N. Raab-Traub,et al.  Epstein-Barr virus replication in oropharyngeal epithelial cells. , 1984, The New England journal of medicine.

[49]  M. Epstein,et al.  Epstein–Barr virus-specific cytotoxic T-cell clones restricted through a single HLA antigen , 1982, Nature.